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Machine learning has a great potential to mine potential markers from high-dimensional metabolic data without any a priori
knowledge. Exemplarily, we investigated metabolic patterns of three severe metabolic disorders, PAHD, MCADD, and 3-MCCD,
on which we constructed classiﬁcation models for disease screening and diagnosis using a decision tree paradigm and logistic regres-
sion analysis (LRA). For the LRA model-building process we assessed the relevance of established diagnostic ﬂags, which have been
developed from the biochemical knowledge of newborn metabolism, and compared the models error rates with those of the decision
tree classiﬁer. Both approaches yielded comparable classiﬁcation accuracy in terms of sensitivity (>95.2%), while the LRA models
built on ﬂags showed signiﬁcantly enhanced speciﬁcity. The number of false positive cases did not exceed 0.001%.
 2004 Elsevier Inc. All rights reserved.
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Newborn screening permits the detection of meta-
bolic disorders in newborns during the ﬁrst few days
of life prior to the manifestation of symptoms [1–3].
Due to recent innovations and reﬁnements of the screen-
ing methodology using modern tandem mass spectrom-
etry (MS/MS) more than 20 inherited metabolic
disorders can be detected simultaneously from a single
blood spot by quantifying concentrations of up to 50
metabolites [4,5]. Machine learning techniques oﬀer an
obvious and promising approach to examine high-di-
mensional metabolic data, where manual analysis is te-
dious and time-consuming due to the great number
and complexity. The investigation of novel metabolic1532-0464/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2004.08.009
* Corresponding author. Fax: +43 50 8648 673827.
E-mail address: christian.baumgartner@umit.at (C. Baumgartner).patterns, the construction of classiﬁcation models with
high diagnostic prediction and the discovery of new
clues for unknown causal relations lead to a better
understanding of mined data in metabolic networks
and constitutes a signiﬁcant contribution to preventive
medicine [6].
Our goal was to investigate high-dimensional meta-
bolic data with respect to three severe inborn errors of
metabolism to construct classiﬁcation models for disease
screening and diagnosis. In particular, we focused on
(i) phenylalanine hydroxylase deﬁciency (PAHD), an
amino acid disorder, which includes cases of classic
phenylketonuria (PKU, OMIM No. 261600 [7]) and
hyperphenylalaninemia (non-PKU HPA, OMIM No.
264070) [8,9], (ii) medium-chain acyl-CoA dehydroge-
nase deﬁciency (MCADD, OMIM No. 201450), a fatty
acid oxidation defect [10], and (iii) 3-methylcrotonyl
CoA carboxylase deﬁciency (3-MCCD, OMIM No.
210200), an organic acid disorder [11,12].
90 C. Baumgartner et al. / Journal of Biomedical Informatics 38 (2005) 89–98For the model-building process we applied two di-
rectly interpretable classiﬁcation algorithms, i.e., the
C4.5 decision tree paradigm and binary logistic regres-
sion analysis (LRA), to a metabolome training dataset.
Decision trees optimize classiﬁcation accuracy by reduc-
ing the full feature dimensionality to a relevant feature
subset according to the algorithms internal feature
selection strategy. The aim is to assess the relevance of
metabolic knowledge for the model-building process
by comparing C4.5s feature subset with established
diagnostic ﬂags which have been developed from the
current biochemical knowledge of abnormalities in new-
born metabolism. For this task we built LRA models on
these ﬂags and benchmarked their error rates with those
of the decision tree classiﬁer which does not require any
a priori knowledge for tree construction.2. Metabolic data
Metabolites analyzed by modern MS/MS employing
appropriate internal standards can be quantiﬁed very
rapidly, sensitively and accurately requiring only mini-
mal sample preparation [1]. For MS/MS analysis a sin-
gle blood sample, which has been taken within few
days after the newborns birth, is suﬃcient. This screen-
ing methodology creates a high-dimensional metabolic
dataset of each newborn including concentration values
of more than 40 metabolites (14 amino acids and 29
fatty acids, see Table 1).
Our experimental datasets were anonymously pro-
vided from the newborn screening program of the State
of Bavaria, Germany, between 1999 and 2002. For our
train-and-test design cycle we focused on one represen-
tative disorder of the amino acid, one of the fatty acid
oxidation, and one of the organic acid metabolism, each
of them showing a relatively high incidence in-betweenTable 1
Overview of metabolites measured from MS/MS analysis
Amino acids (symbols) Fatty acids (symbols)
Alanine (Ala) Free carnitine (C0)
Arginine (Arg) Acetyl-carnitine (C2)
Argininosuccinate (Argsuc) Propionyl-carnitine (C3)
Citrulline (Cit) Butyryl-carnitine (C4)
Glutamate (Glu) Isovaleryl-carnitine (C5)
Glycine (Gly) Hexanoyl-carnitine (C6)
Methionine (Met) Octanyl-carnitine (C8)
Ornitine (Orn) Decanoyl-carnitine (C10)
Phenylalanine (Phe) Dodecanoyl-carnitine (C12
Pyroglutamate (Pyrglt) Myristoyl-carnitine (C14)
Serine (Ser) Hexadecanoyl-carnitine (C
Tyrosine (Tyr) Octadecanoyl-carnitine (C1
Valine (Val) Tiglyl-carnitine (C5:1)
Leucine + Isoleucine (Xle) Decenoyl-carnitine (C10:1)
Myristoleyl-carnitine (C14:
Fourteen amino acids and 29 fatty acids are analyzed from a single blood stheir group of disorders (PAHD, n = 94 cases including
43 cases of classic PKU and 51 cases of non-PKU HPA,
classic MCADD, n = 63 cases, and 3-MCCD, n = 22
cases). Unfortunately, the number of cases of further
screened metabolic disorders was too small (n < 5 cases)
for useful examination.
Based on the given number of PAHD, MCADD, and
3-MCCD cases we sampled a statistically representative
control group from the newborn screening (NBS) data-
base (600,000 entries, end of year 2002) using a rate of
1:15–50 (disorder to controls). The PAHD sub-data-
base thus contains all 94 cases designated as conﬁrmed
PAHD and 1241 randomly sampled controls, i.e., each
500th case from NBS controls. The MCADD and
3-MCCD sub-databases consist of all 63 and 22 cases
designated as classic MCADD and 3-MCCD, and again
1241 controls. In our study population ‘‘controls’’ repre-
sent individuals without veriﬁed cases of known meta-
bolic disorders.
A much larger randomly sampled control database of
98,411 cases, i.e., one sixth of the NBS control database,
serves to estimate the real speciﬁc power of our con-
structed models. Table 2 gives a short clinical overview
of the investigated disorders (enzyme defects, symptoms,
proposed treatments, and diagnostic tests) [7,13–15].3. Process of data analysis
3.1. Overview of data mining steps
The data analysis process constructing classiﬁcation
models on high-dimensional metabolic data is illustrated
in Fig. 1. We constructed classiﬁcation models using
C4.5 decision tree paradigm and LRA. Both models
were trained and 10-fold-cross validated according to a
two-class problem on a training dataset containing nFatty acids (symbols)
Hexadecenoyl-carnitine (C16:1)
Octadecenoyl-carnitine (C18:1)
Decenoyl-carnitine (C10:2)
Tetradecadienoyl-carnitine (C14:2)
Octadecadienoyl-carnitine (C18:2)
Hydroxy-isovaleryl-carnitine (C5-OH)
Hydroxytetradecadienoyl-carnitine (C14-OH)
Hydroxypalmitoyl-carnitine (C16-OH)
) Hydroxypalmitoleyl-carnitine (C16:1-OH)
Hydroxyoleyl-carnitine (C18:1-OH)
16) Dicarboxyl-butyryl-carnitine (C4-DC)
8) Glutaryl-carnitine (C5-DC)
Methylglutaryl-carnitine (C6-DC)
Methylmalonyl-carnitine (C12-DC)
1)
pot using MS/MS. The concentrations are given in lmol/L.
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C. Baumgartner et al. / Journal of Biomedical Informatics 38 (2005) 89–98 91cases of disorder (PAHD: n = 94, MCADD: n = 63 and
3-MCCD: n = 22) and a randomly sampled control
group (n = 1241). The decision tree classiﬁer optimises
classiﬁcation accuracy by reducing full metabolite
dimensionality, while the LRA model was constructed
on the biochemical knowledge—using diagnostic ﬂags
as input variables—with the goal to assess the metabolic
knowledge for the model-building process. Finally, the
models were validated on a larger dataset of 100,000
controls to estimate the false positive rate representative
for a real screening population.
Although the use of separate datasets for the model-
building process is preferred when enough data is avail-
able (see larger control database), the number of cases
designated as a metabolic disorder was too small to sep-
arate them into training and test sets so that cross-vali-
dation was proposed. We also tested the classiﬁers
trained from the diﬀerent disorders against each other
by validating each model with all cases of disorder
which the model was not built on (e.g., the PAHD mod-
el was validated on all cases of MCADD and 3-MCCD
to demonstrate the models speciﬁc behaviour for the
screened disease it was developed for).
3.2. Classiﬁcation algorithms
Decision trees. Decision trees are rooted, usually
binary trees, with simple classiﬁers placed at each inter-
nal node and a class label at each leaf. These simple
classiﬁers associated with the internal nodes are in
the majority of algorithms comparisons between an
input variable and a ﬁx value. Decision trees are gener-
ally trained by means of a top down growth procedure,
which starts from the root node and greedily chooses a
split of the data that maximizes some cost function,
usually a measure of the class purity of the two sub-
groups deﬁned by the split. After choosing a split,
the subgroups are mapped to the two child nodes. This
procedure is then recursively applied to the children,
and the tree grows until some stopping criterion is
met. If the resulting tree is too complex (and, therefore,
often overﬁtted) some of the branches can be pruned.
The algorithm most often used to generate decision
trees is C4.5 and C5.0, respectively. These algorithms
select the next node to place in the tree by computing
the information gain (IG) for all candidate features.
Information gain is a measure how well the given fea-
ture A separates the remaining training data by expect-
ing a reduction of entropy (E), a measure of the
impurity in the data [16–20].
EðSÞ ¼
X
c2C
 jScjjSj : ln
jScj
jSj ð1Þ
IGðS;AÞ ¼ EðSÞ 
X
v2V ðAÞ
jSvj
jSj :EðSvÞ: ð2Þ
Fig. 1. Experimental design of model-building on high-dimensional metabolic data. Several intermediate data mining steps are performed resulting
in a classiﬁcation model with high diagnostic prediction.
92 C. Baumgartner et al. / Journal of Biomedical Informatics 38 (2005) 89–98S represents the data collection, jSj its cardinality, C is
the class collection, Sc the subset of S containing items
belonging to class c, V (A) is the set of all possible values
for feature A, Sv is the subset of S for which A has value
v. For our experiments we used C4.5 for tree construc-
tion with pruning option.
Logistic regression analysis. We constructed classiﬁ-
cation models on diagnostic ﬂags using logistic regres-
sion analysis, which is widely used in medical
applications. LRA constructs a linear separating hyper-
plane between two datasets (cases of disorder and
controls) which have to be distinguished by the classiﬁ-
ers. This hyperplane is mathematically described by a
linear discriminant function z = f (x1, . . . ,xn) = b1x1 +
b2x2 +    + bnxn + c. Here, x1, . . . ,xn are the input vari-
ables. The coeﬃcients b1, . . . ,bn and the constant c have
to be learned by the method.
The distance from the hyperplane is considered as
probability measure of class membership based on a
so-called logistic function p = 1/(1 + ez), where p is
the conditional probability of the form P (z = 1jx1, . . .,
xn) and z the logit (discriminant function) of the model.
The class membership is indicated by a cut-oﬀ value
(p = 0.5 by default, p < 0.5 classiﬁes controls andpP 0.5 cases of disorder). LRA uses a maximum likeli-
hood method which maximizes the probability of getting
the observed results given the ﬁtted coeﬃcients [21].
3.3. Diagnostic ﬂags
In NBS labs diagnostic ﬂags are routinely used to
pre-screen newborns that are highly suspicious for the
screened disorders. The procedure how these ﬂags have
been modelled is brieﬂy sketched by an example.
In the abnormal PAHD metabolism the essential
amino acid Phe can not be metabolized to Tyr due to
a blockade of the enzyme phenylalanine hydroxylase.
Therefore, Phe shows strongly elevated concentration
levels accompanied by slightly decreased Tyr concentra-
tions. The diagnostic ﬂags for PAHD contain the key
marker Phe showing the most signiﬁcant concentration
changes and additionally the ratio of Phe/Tyr represent-
ing the block of the enzyme phenylalanine hydroxylase.
For our experiments we used ﬂags, which were devel-
oped by biochemical and medical experts of the Bavar-
ian newborn screening program, as summarized in
Table 3. NBS centres worldwide use such decision rules
with slight modiﬁcations for disease screening [22,23].
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The discriminatory power of the models was evalu-
ated from stating all true positive (TP), true negative
(TN), false positive (FP), and false negative (FN) cases.
We used sensitivity (Sn), speciﬁcity (Sp), positive predic-
tive value (PPV) and accuracy (Acc = (TP + TN)/all
cases) as measure of classiﬁcation accuracy.
For both approaches the model-building process was
validated using 10-fold-cross validation on our training
datasets which has been proved to be statistically good
enough in evaluating the classiﬁcation accuracy of the
models [18]. Traditionally, 10-fold-cross validation uses
‘‘train on 9-folds, test on onefold.’’ For our experiments
we used the publicly available, widespread, and compre-
hensive data mining tool set WEKA (http://www.cs.wai-
kato.ac.nz/~ml/weka) to perform classiﬁcation and
cross-validation. The WEKA tool constructs LRA mod-
els based on the default cut-oﬀ of p = 0.5 [18].4. Metabolic patterns
Metabolic patterns mined from the decision tree par-
adigm—the nodes of the generated tree represent the rel-
evant feature subset—and basic statistical analysis are
summarized in Table 3. The detected metabolites (tree
nodes) are well comparable to the established diagnostic
metabolites/ﬂags representing the present metabolic
knowledge. In particular, the mined metabolites Phe
and Tyr (PAHD), C8 and C10:1 carnitines (MCADD)
and C5-OH carnitine (3-MCCD) represent the estab-
lished markers known from the disorders metabolism
[15]. However, the decision tree paradigm only selects
single metabolites with highest information gain,
whereas diagnostic ﬂags also take interacting metabo-
lites (ratios) into account. Easy statistical analysis as
illustrated in Table 3 showed that the ratio Phe/Tyr,
for instance, further increases the relative concentration
changes compared to the single markers (Phe/Tyr
+876% vs. Phe +601% and Tyr 31% alone, Table 3).
However, all presented ratios (Phe/Tyr, C8/C10, C8/
C6, and C5-OH/C3) revealed an enhanced coeﬃcient
of variation (CV), predominantly observed in the con-
trol groups. It is of interest to note that each disorder
is characterized by one key metabolite i.e., Phe for
PAHD, C8 for MCADD and C5-OH for 3-MCCD
showing a signiﬁcant concentration enhancement with
a moderate CV (<1).5. Screening models
Following the process of data analysis decision tree
and LRA models were trained and 10-fold-cross vali-
dated on pre-selected training datasets. Classiﬁcation
Table 4a
Classiﬁcation accuracy of decision tree and LRA models trained and cross-validated on a small training set
Disorder (No. of cases) Classiﬁcation model Model input
variables
Sn (%) FN (No.
of cases)
Sp
(%)
FP (No.
of cases)
Acc (%) Tree structure of C4.5 classiﬁer/logit
of LRA models z = a0 + a1 m1+   + an mn
Standard error
of coeﬃcients
RMS
error
PAHD (n = 94) Decision tree classiﬁer Phe 96.809 3 99.758 3 99.551 Phe < = 115.58: control 0.0678
Tyr Phe > 115.58
Ala j Ty r < = 95.92: PAHD
j Tyr > 95.92
j j Ala < = 686.13: PAHD
j j Ala > 686.13: control
LRA built on diagnostic ﬂags Phe 96.809 3 99.758 3 99.551 14.776 2.622 0.0598
Phe/Tyr +0.0738 Æ Phe 0.015
+2.2157 Æ Phe/Tyr 0.519
Phe* 93.617 6 99.678 4 99.251 11.8681 1.429 0.0687
+0.081 Æ Phe 0.011
MCADD (n = 63) Decision tree classiﬁer C8 95.238 3 99.517 6 99.310 C10:1 <= 0.37 0.0813
C10:1 j C8 <= 0.46: control
C16 j C8 > 0.46
j j C16 <= 3.16: MCADD
j j C16 > 3.16
j j j C8 <= 1.48: control
j j j C8 > 1.48: MCADD
C10:1 > 0.37: MCADD
LRA built on diagnostic ﬂags C8 95.238 3 99.678 4 99.463 8.5391 2.394 0.0658
C10:1 +7.1856 Æ C8 2.865
C6 +11.0392 Æ C10:1 4.092
C8/C10 1.6439 Æ C6 2.893
C8/C6 0.1836 Æ C8/C10 0.060
0.1774 Æ C8/C10 1.837
C8* 95.238 3 99.839 2 99.617 7.5362 0.746 0.0595
+5.7931 Æ C8 0.764
3-MCCD (n = 22) Decision tree classiﬁer C5-OH 95.455 1 99.839 3 99.683 C5–OH <= 0.41: Control 0.0563
C6 C5–OH > 0.41
j C6 <= 0.37: 3-MCCD
j C6 > 0.37: control
LRA built on diagnostic ﬂags C5-OH 90.909 2 99.919 1 99.762 722.52 3935.91 0.0486
C5-OH/C3 +1054.41 Æ C5-OH 5719.10
248.09 Æ C5-OH/C3 1348.61
C5-OH* 95.455 1 99.919 1 99.942 47.349 48.291 0.0404
+63.205 Æ C5-OH 65.095
n, number of PAHD, MCADD and 3-MCCD cases, No, number of FN and FP cases. Classiﬁcation results are given in terms of sensitivity (Sn), speciﬁcity (Sp) and accuracy (Acc). The generated
C4.5 tree structures as well as the logit z of the LRA models and the standard error of their coeﬃcients are given. For both algorithms the root mean squared (RMS) error, which is a measure of
success of numeric prediction, is shown. The asterisk (*) highlights those LRA models built on the diseases predominant metabolite (see Table 3, Disorder/controls). Tenfold-cross validation was
applied to validate both classiﬁers.
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accuracy (Acc) is given in Table 4a. In addition to the
parameters Sn, Sp and PPV we also denounce the gener-
ated tree structure as well as the logit of the LRA model
and its standard error of the coeﬃcients, and for both
approaches the root mean squared (RMS) error, a
measure of success of numeric prediction. Both the
decision tree and LRA model for PAHD showed equal
classiﬁcation accuracy (Sn = 96.809%, Sp = 99.758%,
and Acc = 99.551%). The MCADD models error rates
were comparable to the PAHD ones. Only the decision
tree model yielded a slightly reduced speciﬁcity. The
3-MCCD models achieved the highest classiﬁcation
accuracy showing only small alterations in sensitivity
and speciﬁcity.
However, to estimate speciﬁcity and positive predic-
tive value (PPV) representative for a real screening pop-
ulation we validated our models on a larger control
database of approximately 100,000 cases. All validation
results based on a real screening population are summa-
rized in Table 4b. As expected, the speciﬁcity of both
models decreased, while the number of false positive
cases of the decision tree models was 6–16th fold re-
duced compared to that of the LRA/ﬂag approach.
For instance, considering Phe, and Phe/Tyr as LRA
model input variables, the most speciﬁc PAHD model
was established showing a Sp of 99.905% and a PPV
of 49.5%, respectively. In other words, only a fraction
of 93 FP cases (i.e., 0.0009% out of 98,411 controls)Table 4b
Classiﬁcation accuracy of decision tree and LRA models validated on a larg
Disorder (No. of cases) Classiﬁcation model Model input
variables
PAHD (n = 94) Decision tree classiﬁer Phe
Tyr
Ala
LRA built on diagnostic ﬂags Phe
Phe/Tyr
Phe*
MCADD (n = 63) Decision tree classiﬁer C8
C10:1
C16
LRA built on diagnostic ﬂags C8
C10:1
C6
C8/C10
C8/C6
C8*
3-MCCD (n = 22) Decision tree classiﬁer C5-OH
C6
LRA built on diagnostic ﬂags C5-OH
C5-OH/C3
C5-OH*
n, number of PAHD, MCADD, and 3-MCCD cases, No. number of FN an
speciﬁcity (Sp), positive predictive value (PPV), and accuracy (Acc). Sp, PPV a
estimate speciﬁcities of a representative screening population. Sn remain unch
built on the diseases predominant metabolite (see Table 3, Disorder/controlwas wrongly classiﬁed. Testing the PAHD model with
all MCADD and 3-MCCD cases no additional false
negative cases were observed, because abnormal PAHD
metabolism only alters amino acid, but not fatty acid
concentrations. In analogy, no false negative cases were
observed when checking the MCADD or 3-MCCD
models with all PAHD/3-MCCD or PAHD/MCADD
cases, respectively.
For MCADD our results yielded a diﬀerent picture.
Constructing a model on the diagnostic ﬂags (model in-
puts are three single metabolites and two ratios) the
number of FP cases could be reduced from 915 to 55
false positive cases compared to the decision tree clas-
siﬁer. The best classiﬁcation accuracy (Sn = 95.2%,
Sp = 99.992%, PPV = 88.2%) was obtained by building
the model solely on the predominant marker C8 carni-
tine which basically can be explained by the dramatic
concentration changes of C8 caused by the erroneous
fatty acid metabolism of MCADD (cf. increase of
mean concentration level of +3649%, Table 3). The
ﬂags C6, C10:1, C8/C10, and C8/C6 yielded a promis-
ing impact (mean concentration changes 159–750%)
and moderate CV in the MCADD class (<0.92), but
they were not able to further increase speciﬁcity. How-
ever, the false positive rates for MCADD between dif-
ferent screening programs most likely vary because of
diﬀerences in acylcarnitine analysis and proﬁling. C8,
the predominant, but not speciﬁc marker for MCADD,
which is elevated in several other disorders (e.g.,er control database
Sn (%) FN (No.
of cases)
Sp (%) FP (No.
of cases)
PPV (%) Acc (%)
96.809 3 99.404 587 13.41 99.401
96.809 3 99.905 93 49.46 99.903
95.745 4 99.885 113 44.34 99.881
95.238 3 99.070 915 6.15 99.068
95.238 3 99.944 55 52.17 99.941
95.238 3 99.992 8 88.24 99.989
95.455 1 99.627 367 5.41 99.626
90.909 2 99.955 44 33.33 99.955
95.455 1 99.957 42 33.33 99.956
d FP cases. Classiﬁcation results are given in terms of sensitivity (Sn),
nd Acc were re-evaluated on a larger database of 100,000 controls to
anged (see results Table 4a). The asterisk (*) highlights the LRA models
s).
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deﬁciency), can be used to pre-screen several fatty oxi-
dation disorders. Both presented models including
additional markers to C8 are speciﬁc for MCADD
which is important when physicians consider diﬀeren-
tial diagnostic aspects.
The classiﬁcation models for 3-MCCD diﬀered signif-
icantly from that of PAHD and MCADD as both ap-
proaches showed the lowest classiﬁcation error rates.
The LRA model built on the predominant marker C5-
OH, however, yielded the best classiﬁcation accuracy.
The ratio C5-OH/C3 seems to be redundant.6. Procedure to optimize sensitivity
In newborn screening the declared aim is to optimise
sensitivity to 100% and to increase speciﬁcity as far as
possible. This assignment is of high importance as ethi-
cal arguments and cost eﬀectiveness related to an erro-
neous diagnosis are concerned. However, the presented
models showing high speciﬁcity do not always have opti-
mal Sn of 100%. Exemplarily, Fig. 2 illustrates a proce-
dure to optimize sensitivity of our most speciﬁc PAHD
model (constructed on Phe and Phe/Tyr) by changing
the default cut-oﬀ level from p = 0.5 stepwise to
p = 0.25, 0.15, 0.1, and 0.01. By reducing the cut-oﬀ
value to p = 0.15, all PAHD cases can be correctlyFig. 2. Procedure to optimize sensitivity of the LRA model for PAHD
constructed on the input variables Phe and Phe/Tyr: costs to optimize
sensitivity by reduction of speciﬁcity are illustrated. The changes of
sensitivity (%), speciﬁcity (%) and absolute number of FP cases (n) are
given for cut-oﬀ values of p = 0.5, 0.25, 0.15, 0.1, and 0.01. The arrow
indicates 100% sensitivity and a lower speciﬁcity of 99.818% (n = 179
FP cases) at p = 0.15 compared to p = 0.5 by default showing a
sensitivity of 96.809% and a speciﬁcity of 99.905% (n = 93 FP cases).
The cut-oﬀ optimization was performed on full training data (not
validated).classiﬁed (Sn = 100%, arrow in Fig. 2), while the num-
ber of FP cases increases from 93 to 179. Therefore, Sp
demounted from 99.905 to 99.818%. However, this
procedure to optimize sensitivity of the regression
model was performed only on the full training dataset,
thus giving too optimistic results in general. For cross-
or leave-one-out validation, which is recommended, if
training sets are small, the entire model-building pro-
cess including optimisation of the cut-oﬀ value, and
classiﬁcation has to be repeated in each cross-valida-
tion training subset. Currently, the validation proce-
dure is in progress, these results have to be presented
later.7. Discussion
To satisfy the ever growing need for eﬀective screen-
ing and diagnostic tests MS/MS provides a very high
throughput and has the potential to be highly accurate.
The complexity of analysed high-dimensional metabolic
data using MS/MS requires machine learning and data
mining techniques to support the classiﬁcation of disease
and the identiﬁcation of potentially useful diagnostic
markers. In turn, the identiﬁcation of key metabolites
could shed light on the nature of the disorder.
However, there are many data mining techniques for
the processing and general learning of high-dimensional
data in proteomics/metabolomics. Current research
focuses on the detection of regions of interest in ma-
trix-assisted desorption/ionization-time of ﬂight mass
spectra to mine diﬀerences in the protein pattern
between healthy and diseased persons using established
supervised and unsupervised methods [24,25]. Our
experiments were not directly applied to the protein
mass spectra, but were performed on data by the con-
version of raw mass spectra into clinically meaningful
results (amino acid and fatty acid concentrations) [1].
We investigated two diﬀerent approaches to build clas-
siﬁcation models on provided newborn screening data
with high diagnostic prediction. Machine learning oﬀers
the advantage that markers are found without any other
a priori assumptions or conditions, and our results cor-
respond well to the established biochemical knowledge
[8–12]. In our approach we used the decision tree para-
digm to identify potentially useful metabolites (nodes of
tree) by computing the information gain for all candi-
date features. However, ﬁlter based selection techniques
like information gain or correlation-based ﬁlters also
yield promising results, but solely select single attributes
as subsets [26,27]. Building LRA models on single
metabolites and ratios, which reﬂect the interaction
of single metabolites in newborn metabolism (cf.
PAHD: Phe ›\ Tyr ﬂ) Phe/Tyr), the number of false
positive cases could be diminished signiﬁcantly (up to
6–16 times) compared to the decision tree classiﬁer.
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lism modelled as ratios of interacting attributes thus
provides an important contribution to enhance a mod-
els speciﬁc power, while sensitivities in both approaches
remain unchanged.
However, no classiﬁcation model in both approaches
achieved 100% sensitivity. In this context we brieﬂy
sketched a procedure showing the best trade-oﬀ between
optimal sensitivity and speciﬁcity that can be accepted
by adjusting the cut-oﬀ value in LRA. As mentioned be-
fore, further validation studies are warranted.
In addition to the decision tree classiﬁer we used
LRA, which shows highest discriminatory performance
as we could demonstrate in prior experiments compar-
ing various classiﬁcation algorithms on metabolic data
[27]. Some of them are well accepted in current proteo-
mic research as other authors described [28]. However,
both paradigms can be classiﬁed as directly interpretable
techniques, which represent their data relations in an
explicit way like a probabilistic model (LRA) or a tree
structure, and so they ﬁnd more acceptance in a clinical
ambience.8. Conclusion
Data mining in MS/MS data enables us to identify
disease state metabolites without any a priori knowl-
edge. The consideration of biochemical knowledge for
the model-building process by combining interacting
disease state metabolites revealed a further increase of
the classiﬁers discriminatory performance and lead to
a signiﬁcant increase of the speciﬁc power of our screen-
ing models. Our models achieved sensitivity values
>95.2%. The number of FP cases in all three disorders
did not exceed 0.001%.
The presented approach, which considers mining
techniques and expert knowledge for the model-building
process, permits the construction of classiﬁcation rules
with high diagnostic prediction.Acknowledgments
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